Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Characteristics of population in 2018, stratified by lab testing for vitamin D levelPopulation not tested for vitamin D level (N = 157,073)Population tested for vitamin D level (N = 38,384)VariablePercentage (95% confidence interval)Percentage (95% confidence interval)GenderMale50.9 (50.7 to 51.2)32.4 (32.0 to 32.9)Age group in years19: 4037.6 (37.3 to 37.8)22.6 (22.1 to 23.0)41 to 6036.6 (36.3 to 36.8)35.0 (34.5 to 35.5)61 to 8020.8 (20.6 to 21.0)33.5 (33.0 to 33.9)81+5.0 (4.9 to 5.1)9.0 (8.7 to 9.3)Deductible class in CHF30039.4 (39.2 to 39.6)59.7 (59.2 to 60.2)50012.4 (12.3 to 12.6)17.0 (16.6 to 17.4)10005.6 (5.4 to 5.7)4.3 (4.1 to 4.5)150010.1 (10.0 to 10.3)5.5 (5.3 to 5.7)20005.4 (5.2 to 5.5)2.4 (2.3 to 2.6)250027.1 (26.9 to 27.3)11.0 (10.7 to 11.3)Health planUnrestricted access14.3 (14.1 to 14.5)22.6 (22.2 to 23.0)Gatekeeping by GP25.4 (25.2 to 25.6)26.1 (25.7 to 26.6)Gatekeeping by telemedical provider28.7 (28.5 to 29)26.5 (26.1 to 27.0)HMO31.6 (31.3 to 31.8)24.7 (24.3 to 25.2)Supplementary insurance coverageYes24.2 (24.0 to 24.4)29.6 (29.1 to 30.0)Geographic regionEastern14.6 (14.4 to 14.8)11.9 (11.5 to 12.2)Central9.8 (9.6 to 9.9)9.0 (8.7 to 9.3)Mittelland22.3 (22.1 to 22.5)21.6 (21.2 to 22.0)Northwest13.7 (13.5 to 13.9)14.3 (13.9 to 14.6)Western21.6 (21.4 to 21.8)25.4 (25.0 to 25.9)Zurich18.0 (17.8 to 18.2)17.8 (17.4 to 18.2)Urbanity levelsaRural10.5 (10.3 to 10.6)8.5 (8.2 to 8.8)Peri-urban22.1 (21.9 to 22.3)19.3 (18.9 to 19.7)Urban small8.8 (8.7 to 9.0)8.4 (8.1 to 8.6)Urban midsize27.8 (27.6 to 28.1)27.1 (26.7 to 27.6)Urban large30.8 (30.5 to 31.0)36.7 (36.2 to 37.2)PregnancyYes2.4 (2.3 to 2.4)3.2 (3.1 to 3.4)Chronic morbiditiesb074.2 (74.0 to 74.4)47.7 (47.2 to 48.2)113.6 (13.4 to 13.7)22.5 (22.1 to 23.0)27.2 (7.1 to 7.3)15.4 (15.0 to 15.7)≥35.0 (4.9 to 5.1)14.5 (14.1 to 14.8)Renal diseasebYes0.03 (0.02 to 0.04)0.3 (0.2 to 0.3)OsteoporosisbYes1.1 (1.1 to 1.2)6.8 (6.5 to 7.0)EpilepsybYes0.2 (0.2 to 0.2)0.4 (0.3 to 0.4)HyperparathyroidismbYes0.01 (0.01 to 0.02)0.2 (0.1 to 0.2)HIVbYes0.1 (0.1 to 0.2)0.4 (0.4 to 0.5)GlucocorticoidsbYes1.7 (1.7 to 1.8)5.1 (4.9 to 5.3)Vitamin D supplementationbYes4.0 (3.9 to 4.1)23.6 (23.2 to 24.0)CHF Swiss francs, GP General practitioner, HMO Health Maintenance Organization, HIV Human Immunodeficiency Virusabased on definitions of Federal Statistical Officebbased on pharmaceutical claims

Source: Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cross-sectional study.

Cross-sectional study

Examines a population at a particular point in time.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland

Cross-sectional study · BMC Health Services Research · 2020

Original publication title

Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland

Stefan Essig; Christoph Merlo; Oliver Reich; Maria Trottmann

© The Author(s) 2020

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Despite recommendations for routine vitamin D supplementation, vitamin D testing of low risk individuals is common and increasing in Switzerland.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

There is consensus that vitamin D supplementation is often indicated but population-based screening by laboratory testing for vitamin D deficiency is inadequate. Testing should be restricted to people at high risk of severe deficiency. This study describes the current lab testing for vitamin D deficiency in the adult population of Switzerland.

Source: Background

Abstract: What methods does the paper describe?

We assessed Swiss health insurance data (SWICA) for incidence of lab testing for vitamin D levels, comparing the years 2015 and 2018. Claims were analyzed for associations between lab testing and age, sex, medical indications, insurance status and geographic location in multivariable regression analyses. We also estimated the costs of vitamin D testing.

Source: Methods

Abstract: Results

Data from 200,043 and 200,046 persons for 2015 and 2018, respectively, were analyzed. Vitamin D level was tested in 14% of the sample population in 2015 and 20% in 2018. Testing increased by 69% for individuals aged 26 to 30. Testing was associated with being middle-aged to young senior citizens, female, medical indications (pregnancy, renal disease, osteoporosis, hyperparathyroidism, HIV, glucocorticoid intake), more chronic conditions, having a mandatory insurance with a low deductible, additional insurance coverage, and living in urban areas. We estimate that the total laboratory cost to mandatory insurance was about 90 million Swiss francs in 2018.

Source: Results

Abstract: Conclusions

Despite recommendations for routine vitamin D supplementation, vitamin D testing of low risk individuals is common and increasing in Switzerland.

Source: Conclusions
Authors’ abstract

Background

There is consensus that vitamin D supplementation is often indicated but population-based screening by laboratory testing for vitamin D deficiency is inadequate. Testing should be restricted to people at high risk of severe deficiency. This study describes the current lab testing for vitamin D deficiency in the adult population of Switzerland.

Methods

We assessed Swiss health insurance data (SWICA) for incidence of lab testing for vitamin D levels, comparing the years 2015 and 2018. Claims were analyzed for associations between lab testing and age, sex, medical indications, insurance status and geographic location in multivariable regression analyses. We also estimated the costs of vitamin D testing.

Results

Data from 200,043 and 200,046 persons for 2015 and 2018, respectively, were analyzed. Vitamin D level was tested in 14% of the sample population in 2015 and 20% in 2018. Testing increased by 69% for individuals aged 26 to 30. Testing was associated with being middle-aged to young senior citizens, female, medical indications (pregnancy, renal disease, osteoporosis, hyperparathyroidism, HIV, glucocorticoid intake), more chronic conditions, having a mandatory insurance with a low deductible, additional insurance coverage, and living in urban areas. We estimate that the total laboratory cost to mandatory insurance was about 90 million Swiss francs in 2018.

Conclusions

Despite recommendations for routine vitamin D supplementation, vitamin D testing of low risk individuals is common and increasing in Switzerland.

Publication and source details

Original title: Potentially inappropriate testing for vitamin D deficiency: a cross-sectional study in Switzerland

Stefan Essig; Christoph Merlo; Oliver Reich; Maria Trottmann

BMC Health Services Research · 2020

© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Swiss Medical Board (www.swissmedicalboard.ch)Unrestricted grantEssig Stefan

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:46:04.315863+00:00

DOI: 10.1186/s12913-020-05956-2 · PMC7694269